Key Takeaways
- • Pacira BioSciences filed definitive proxy materials on April 28, 2026, urging shareholders to vote for its three board nominees (Christopher Christie, Samit Hirawat MD, and Thomas Wiggans) using the BLUE proxy card ahead of the June 9, 2026 annual meeting.
- • Activist hedge fund DOMA Perpetual Capital Management nominated three competing board candidates in March 2026, citing concerns over Pacira's IP litigation strategy and the execution risk of its 5x30 strategic plan, effectively pushing the company toward a potential sale.
- • Pacira reported strong Q1 2026 results and highlighted 35% stock appreciation since launching its 5x30 strategy, positioning the company as "stronger than at any point in its history" and defending its current strategic direction against DOMA's disruptive proxy contest.
- • DOMA Perpetual argues that Pacira's board is "gambling with shareholder money" through continued IP litigation and an "unproven, cash-burning" 5x30 plan, signaling fundamental disagreement over capital allocation and portfolio strategy.
- • The proxy battle centers on competing visions for Pacira's future: management's long-term value creation plan versus activist pressure for strategic alternatives including a potential asset sale or merger.
Summary
Pacira BioSciences initiated a shareholder campaign in late April 2026 to defend its board against an activist challenge from DOMA Perpetual Capital Management. On April 28, 2026, Pacira filed definitive proxy materials and mailed a letter to shareholders recommending votes for its three board nominees—Christopher Christie, Samit Hirawat MD, and Thomas Wiggans—on the BLUE proxy card in advance of the June 9, 2026 annual stockholder meeting. The company characterized its nominees as "highly qualified" and explicitly opposed DOMA's competing slate, which the company described as "underqualified."
DOMA Perpetual initiated its activist campaign in March 2026 by nominating three board candidates, positioning the hedge fund as a significant dissenter from Pacira's current strategic trajectory. DOMA's core grievance centers on two fronts: the company's ongoing intellectual property litigation strategy and the execution risk associated with Pacira's 5x30 strategic plan. According to DOMA's messaging, the board is "gambling with shareholder money" through these commitments, and the activist fund has publicly advocated for strategic alternatives, including a potential sale of the company. This messaging suggests DOMA believes Pacira's standalone strategy undervalues the business and that shareholders would benefit from exploring third-party acquisition interest.
Pacira's management responded by emphasizing operational momentum and financial performance. The company highlighted that it entered 2026 "stronger than at any point in its history," supported by strong Q1 2026 results and stock appreciation of over 35% since the 5x30 strategy launch. Pacira emphasized its protected intellectual property position, describing a "strong patent portfolio" and ongoing disciplined capital deployment to build a "complementary and diversified portfolio." Management framed the proxy contest as a choice between proven operational execution and DOMA's "disruptive, misguided" challenge to the company's long-term value creation plan.
The proxy battle reflects a classic institutional investor tension: activist pressure for near-term strategic alternatives or operational changes versus incumbent management's multi-year transformation thesis. With the June 9, 2026 annual meeting approaching, both sides have escalated shareholder communications to secure voting support. For institutional investors and hedge fund managers evaluating Pacira, the contest outcome will determine whether the company continues its current 5x30 execution or pursues alternative strategic options.
DOMA Perpetual initiated its activist campaign in March 2026 by nominating three board candidates, positioning the hedge fund as a significant dissenter from Pacira's current strategic trajectory. DOMA's core grievance centers on two fronts: the company's ongoing intellectual property litigation strategy and the execution risk associated with Pacira's 5x30 strategic plan. According to DOMA's messaging, the board is "gambling with shareholder money" through these commitments, and the activist fund has publicly advocated for strategic alternatives, including a potential sale of the company. This messaging suggests DOMA believes Pacira's standalone strategy undervalues the business and that shareholders would benefit from exploring third-party acquisition interest.
Pacira's management responded by emphasizing operational momentum and financial performance. The company highlighted that it entered 2026 "stronger than at any point in its history," supported by strong Q1 2026 results and stock appreciation of over 35% since the 5x30 strategy launch. Pacira emphasized its protected intellectual property position, describing a "strong patent portfolio" and ongoing disciplined capital deployment to build a "complementary and diversified portfolio." Management framed the proxy contest as a choice between proven operational execution and DOMA's "disruptive, misguided" challenge to the company's long-term value creation plan.
The proxy battle reflects a classic institutional investor tension: activist pressure for near-term strategic alternatives or operational changes versus incumbent management's multi-year transformation thesis. With the June 9, 2026 annual meeting approaching, both sides have escalated shareholder communications to secure voting support. For institutional investors and hedge fund managers evaluating Pacira, the contest outcome will determine whether the company continues its current 5x30 execution or pursues alternative strategic options.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.